[CAS NO. 477775-14-7] Buloxibutid
PRODUCTS SPECIFICATIONS [477775-14-7]
DESCRIPTION [477775-14-7]
Overview
| MDL | MFCD26936332 |
|---|---|
| Molecular Weight | 475.62 |
| Molecular Formula | C23H29N3O4S2 |
| SMILES | O=C(OCCCC)NS(=O)(C1=C(C2=CC=C(CN3C=CN=C3)C=C2)C=C(CC(C)C)S1)=O |
2 Publications Citing Use of MCE
Summary
AT2 receptor agonist C21 is a druglike selective angiotensin II AT2 receptor agonist with K i values of 0.4 nM and >10 µM for the AT2 receptor and AT1 receptor , respectively [1] .
IC50 & Target
Ki: 0.4 nM (AT2) and >10 µM (AT1) [1]
In Vivo
AT2 receptor agonist C21, with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44mapk, enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 210.25 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1025 mL | 10.5126 mL | 21.0252 mL |
| 5 mM | 0.4205 mL | 2.1025 mL | 4.2050 mL |
| 10 mM | 0.2103 mL | 1.0513 mL | 2.1025 mL |
References
- [1] Wan Y, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004 Nov 18;47(24):5995-6008.
- [2] Schwengel K, Namsolleck P, Lucht K, et al. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. J Mol Med (Berl). 2016;94(8):957-966.
- [3] Fatima N, Patel S, Hussain T. Angiotensin AT2 Receptor is Anti-inflammatory and Reno-Protective in Lipopolysaccharide Mice Model: Role of IL-10. Front Pharmacol. 2021;12:600163.
